EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma

Leonard B Bacharier iD, Jorge F Maspero, Nikolaos G Papadopoulos, Rémi Gagnon, Theresa W Guilbert, Changming Xia, Olivier Ledanois, Mena Soliman

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.71197 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Leonard B Bacharier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Adrenal Cortex Hormones, Anti-Asthmatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials. gov Identifier: NCT02948959..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab improved clinical outcomes in children (aged 6–11 years) with moderate‐to‐severe asthma and type 2 inflammation (baseline blood eosinophil count ≥ 150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥ 20 ppb) in the phase 3 VOYAGE study (NCT02948959). We evaluated dupilumab plus medium‐dose ICS versus placebo plus continued high‐dose ICS in children in VOYAGE.

Methods

Children were randomized to dupilumab 100/200 mg by body weight or placebo every 2 weeks for 52 weeks. Annualized severe exacerbation rates, change from baseline in pre‐bronchodilator percent predicted forced expiratory volume in 1 s (ppFEV 1 ), morning peak expiratory flow (PEF), 7‐item Asthma Control Questionnaire‐Investigator Administered (ACQ‐7‐IA) score, FeNO, blood eosinophil count, and total IgE at Week 52 were assessed.

Results

Data from 184 children were analyzed (dupilumab plus medium‐dose ICS, n = 134; placebo plus high‐dose ICS, n = 50). At Week 52, dupilumab plus medium‐dose ICS versus placebo plus high‐dose ICS significantly reduced exacerbations by 74.3%, and significantly improved ppFEV 1 , morning PEF, ACQ‐7‐IA score, FeNO, and total IgE. There was no significant difference in blood eosinophil counts between the two groups.

Conclusion

In children with moderate‐to‐severe asthma and type 2 inflammation, treatment with dupilumab plus medium‐dose ICS reduced exacerbations and improved lung function and asthma control compared with placebo plus continued high‐dose ICS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAntibodies, Monoclonal, HumanizedAdrenal Cortex HormonesAnti-Asthmatic AgentsHumansChildFemaleMaleAdministration, InhalationTreatment OutcomeDrug Therapy, CombinationDouble-Blind MethodSeverity of Illness IndexForced Expiratory VolumeImmunoglobulin EEosinophils

Stichwörter der Autor:innen

ICS doseasthma controldupilumabexacerbationslung functionpediatric asthma

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabAdrenal Cortex HormonesAnti-Asthmatic AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Monroe Carell Jr. Children's Hospital at Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Fundación CIDEA, Buenos Aires, Argentina.
  • Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
  • Clinique Spécialisée en Allergie de la Capitale, Quebec City, Quebec, Canada.
  • Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, Ohio, USA.
  • Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

ORCID-Profile: Leonard B Bacharier

Förderung

  • This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials. gov Identifier: NCT02948959.

Zitieren

APA

Bacharier, L. B., Maspero, J. F., Papadopoulos, N. G., Gagnon, R., Guilbert, T. W., Xia, C., Ledanois, O., & Soliman, M. (2025). Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71197

Vancouver

Bacharier LB, Maspero JF, Papadopoulos NG, Gagnon R, Guilbert TW, Xia C, et al. Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71197

BibTeX
@article{Bacharier2025,
  author = {Bacharier, Leonard B and Maspero, Jorge F and Papadopoulos, Nikolaos G and Gagnon, Rémi and Guilbert, Theresa W and Xia, Changming and Ledanois, Olivier and Soliman, Mena},
  title = {Dupilumab Plus Medium‐Dose Inhaled Corticosteroid (ICS) Improves Outcomes Compared With Placebo Plus Continued High‐Dose ICS in Children With Uncontrolled Moderate‐to‐Severe Type 2 Asthma},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.71197}
}
Kostenlos starten →